ncRNA-mediated upregulation of FAM83A is associated with poor prognosis and immune infiltration in pancreatic cancer

Wenbo Zou, Hao Wang, Dingguo Wu, Yunyang Wu, Kuiping Zhou, Yuan-Shu Lian, Gengyun Chang, Yuze Feng, Jifeng Liang, Gao HuangFrontiers in Endocrinology 2023 · DOI

TL;DR

Researchers have identified a specific genetic regulatory axis—AL049555.1 / hsa-miR-129-5p / FAM83A—that drives the progression of pancreatic cancer. High expression of the FAM83A gene is strongly linked to poor patient survival and increased immune cell infiltration, marking it as a promising new biomarker and potential target for immunotherapy.

What Problem Does This Paper Address?

Pancreatic cancer (PC) remains one of the deadliest malignancies, with a five-year survival rate hovering around 10%. Because it is often asymptomatic in early stages, most patients are diagnosed late, when surgery is no longer an option and resistance to chemotherapy is common.

While the gene FAM83A was already known to act as an oncogene in several cancers (like lung and breast), its specific regulatory mechanism in pancreatic cancer was poorly understood. Specifically, the authors sought to map the "upstream" regulators—the non-coding RNAs (ncRNAs) that act like a control panel for FAM83A—and determine how this gene influences the tumor's immune microenvironment, which is critical for the success of modern immunotherapies.

Methods

The study employed a "dry lab" to "wet lab" validation approach:

  • Bioinformatics & Data Mining: The team analyzed transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and GTEx across 33 different cancer types. They used the limma R package for differential expression and Cox regression for survival analysis.
  • Regulatory Network Prediction: To find the ncRNAs controlling FAM83A, they used starBase, which integrates multiple prediction algorithms (PITA, miRanda, TargetScan, etc.) to identify microRNA (miRNA) and long non-coding RNA (lncRNA) interactions.
  • Immune Profiling: They used CIBERSORT and TIMER to estimate the abundance of 22 types of immune cells within the tumors based on gene expression patterns.
  • Experimental Validation: Crucially, the authors validated their computational findings using qRT-PCR and immunohistochemistry (IHC) on actual tumor and paracancerous tissues collected from patients at the No. 924 Hospital of PLA in China.

Datasets

  • TCGA (The Cancer Genome Atlas): Primary source for mRNA and clinical data across 33 cancer types.
  • GTEx (Genotype-Tissue Expression): Used as a baseline for normal tissue expression levels.
  • Local Clinical Cohort: Tissue samples from patients at the No. 924 Hospital of PLA Joint Logistic Support Force (Guilin, China) for experimental validation.
  • TISIDB & starBase: Specialized databases for immune-system interactions and RNA-RNA binding predictions.

Key Insights and Ideas

  • The ceRNA "Sponge" Mechanism: The study supports the competing endogenous RNA (ceRNA) hypothesis. In this model, the lncRNA AL049555.1 acts as a "sponge," soaking up the miRNA hsa-miR-129-5p. Since this miRNA normally suppresses FAM83A, the lncRNA's interference leads to an "upregulation" (over-expression) of FAM83A, fueling cancer growth.
  • Pan-Cancer Significance: FAM83A isn't just a PC problem; it was significantly overexpressed in 15 out of 33 cancer types studied, suggesting it is a broad-spectrum oncogenic driver.
  • Immune Microenvironment Link: High FAM83A levels correlated with increased infiltration of M0 macrophages and memory B cells. More importantly, it correlated with the expression of PD-1 (PDCD1), a key immune checkpoint. This suggests that FAM83A might help create an "immune-exhausted" environment that allows the tumor to hide from the immune system.

Key Results

  • Survival Impact: High FAM83A expression was a significant predictor of poor Overall Survival (OS), Disease-Specific Survival (DSS), and Progression-Free Interval (PFI) in pancreatic cancer patients (P < 0.001).
  • The Regulatory Axis: hsa-miR-129-5p was identified as the most pivotal miRNA suppressing FAM83A (correlation r = -0.322, P < 0.001).
  • Diagnostic Accuracy: A prognostic nomogram combining FAM83A expression and clinical "N stage" (lymph node involvement) achieved an AUC of 0.696, indicating a solid ability to predict 1-, 2-, and 3-year survival rates.
  • Mutation Correlation: FAM83A expression was positively linked to common PC mutations, including KRAS (the most frequent driver in PC) and SMAD4.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Bias: The study relies heavily on public databases (TCGA), which may have intrinsic selection biases.
  • Need for Functional Studies: While the correlations are strong, the paper does not perform "knockdown" or "knock-in" experiments (e.g., using CRISPR) in cell lines or animal models to definitively prove that blocking this axis stops tumor growth.
  • Validation Gap: The findings need to be confirmed in a larger, multi-center prospective clinical trial before FAM83A can be used as a standard-of-care biomarker.

In summary, this research provides a roadmap for understanding how non-coding RNAs collaborate to turn on a dangerous oncogene, offering a new potential "weak spot" to target in the fight against pancreatic cancer.

Summary updated

Abstract

<i>FAM83A</i> may be used as a novel survival-related and immune-related biomarker. This information suggests that <i>FAM83A</i> may be a novel therapeutic target for combined or individual treatment for patients with pancreatic cancer.
BibTeX
@inproceedings{zou2023ncrna,
  author = {Wenbo Zou and Hao Wang and Dingguo Wu and Yunyang Wu and Kuiping Zhou and Yuan-Shu Lian and Gengyun Chang and Yuze Feng and Jifeng Liang and Gao Huang},
  title = {{ncRNA-mediated upregulation of FAM83A is associated with poor prognosis and immune infiltration in pancreatic cancer}},
  booktitle = {Frontiers in Endocrinology},
  year = {2023},
  doi = {10.3389/fendo.2023.1093042},
}
Figure